UNSPSC 51332519: Haloperidol intensol

This classification denotes a butyrophenone with the molecular formula C21H23ClFNO2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6387S86PK3, chemically known as (+/-)-haloperidol lactate, but more generally known as haloperidol intensol, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules haloperidol intensol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08005MIG. Most nations, for tariff purposes, schedule haloperidol intensol under HS 29333999.

SMILES: CC(C(=O)O)O.C1CC(CCC1C(=O)CCCN2CCC(CC2)(C3CCC(CC3)CL)O)F.

UNSPSC 51332519 Haloperidol intensol is a Commodity code; however, the recent state and local contract opportunities tagged under it do not align with haloperidol procurement. The three most recent solicitations address naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through a multistate cooperative purchasing vehicle, and a request for information on direct-to-manufacturer prescription programs—none of which concern haloperidol specifically. State and local governments soliciting under this code appear to be sourcing pharmaceuticals and related health products through a mix of county health departments, state pharmacy benefit programs, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and member agencies.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (No. IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with a bid deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (No. S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to distribute through three authorized wholesalers. The code shows limited recent activity that is directly relevant to haloperidol procurement.